Rachel Klemovitch, Assistant Editor04.01.24
Popular March news items centered around, ODT feature articles, new products, and FDA approvals.
This month’s features discussed digital AI solutions for orthopedic extremity surgeries and the benefits and limitations of additive manufacturing in orthopedic instruments and implants.
Stryker was popular in March. Its Gamma4 Hip fracture nailing system is now offered in most European markets after gaining a CE mark in September of last year. The company also finalized its acquisition of the France-based joint replacement company, SERF SAS.
The FDA granted Osteal Therapeutics a Breakthrough Therapy Designation for its VT-X7 which delivers antibiotics directly to infected joint space and surrounding tissue. RevBio also received FDA approval for its first-in-human trial for the company’s regenerative bone adhesive. Study will examine the safety and possible benefit of TETRANITE in replacing metal plates and screws in cranial flap fixation.
1. Study: Robotic Assistance in Cementless TKA Does Not Improve Revision Rates
2. Extreme Fixes for Orthopedic Extremity Surgery
3. Stryker Closes Acquisition of SERF SAS
4. Stryker Launches Gamma4 Hip Fracture Nailing System in Europe
5. Medtronic Rolls Out Intelligent Data Collection for Spine Surgery
6. Print Shop: Insights on Orthopedic Additive Manufacturing
7. Osteal Therapeutics Granted FDA Breakthrough Designation for Joint Infection Therapy
8. Smith+Nephew Becomes Official UFC Partner
9. BellaSeno’s 3D Printed Resorbable Scaffold Was Successfully Used in Surgery
10. FDA Approves First-in-Human Trial for RevBio's Regenerative Bone Adhesive
This month’s features discussed digital AI solutions for orthopedic extremity surgeries and the benefits and limitations of additive manufacturing in orthopedic instruments and implants.
Stryker was popular in March. Its Gamma4 Hip fracture nailing system is now offered in most European markets after gaining a CE mark in September of last year. The company also finalized its acquisition of the France-based joint replacement company, SERF SAS.
The FDA granted Osteal Therapeutics a Breakthrough Therapy Designation for its VT-X7 which delivers antibiotics directly to infected joint space and surrounding tissue. RevBio also received FDA approval for its first-in-human trial for the company’s regenerative bone adhesive. Study will examine the safety and possible benefit of TETRANITE in replacing metal plates and screws in cranial flap fixation.
1. Study: Robotic Assistance in Cementless TKA Does Not Improve Revision Rates
2. Extreme Fixes for Orthopedic Extremity Surgery
3. Stryker Closes Acquisition of SERF SAS
4. Stryker Launches Gamma4 Hip Fracture Nailing System in Europe
5. Medtronic Rolls Out Intelligent Data Collection for Spine Surgery
6. Print Shop: Insights on Orthopedic Additive Manufacturing
7. Osteal Therapeutics Granted FDA Breakthrough Designation for Joint Infection Therapy
8. Smith+Nephew Becomes Official UFC Partner
9. BellaSeno’s 3D Printed Resorbable Scaffold Was Successfully Used in Surgery
10. FDA Approves First-in-Human Trial for RevBio's Regenerative Bone Adhesive